Asset Details
Do you wish to reserve the book?
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
Do you wish to request the book?
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
2024
Overview
Neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced, high-risk breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood-derived indices reflecting systemic inflammation and nutritional status have long been used as predictive and prognostic markers in solid malignancies. This retrospective study investigates whether eight commonly used indices in patients receiving NACT affect pCR and survival. This study includes 624 locally advanced breast cancer patients who received NACT. The biomarker indices were calculated from peripheral blood samples taken two weeks before starting chemotherapy. The indices’ optimal cut-off values were determined using ROC Curve analysis. During a median follow-up period of 42 months, recurrence was detected in 146 patients, and 75 patients died. pCR was observed in 166 patients (26.6%). In univariate analysis, NLR, PLR, SII, PNI, HALP, and HRR were statistically significantly associated (
p
= 0.00;
p
= 0.03;
p
= 0.03;
p
= 0.02;
p
= 0.00;
p
= 0.02 respectively), but in multivariate analysis, only NLR was significantly predictive for pCR(
p
= 0.04). In multivariate analysis, the HGB/RDW score significantly predicted DFS(
p
= 0.04). The PNI score was identified as a marker predicting survival for both OS and PFS (
p
= 0.01,
p
= 0.01, respectively). In conclusion, peripheral blood-derived indices have prognostic and predictive values on pCR and survival. However, further studies are needed to validate our findings.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/92
/ Adult
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - mortality
/ Breast Neoplasms - pathology
/ Female
/ Humanities and Social Sciences
/ Humans
/ Neoadjuvant Therapy - methods
/ Pathologic complete response
/ Science
/ Survival
